HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced it will host a conference call on August 13, 2026, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2026, and provide updates on its strategy to accelerate global adoption of its ambulatory ECG signal platform. The call will be led by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and Chief Financial Officer Timothy Cruickshank, and will include a question-and-answer session following prepared remarks.
The company is developing what it describes as the first-ever cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions, and synthesizing those signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence, enabling physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received FDA clearance in December 2025. The company holds over 20 issued patents related to its technology enablement. These clearances mark significant milestones for the company, as they pave the way for broader clinical adoption and potential improvements in remote cardiac monitoring.
The implications of HeartBeam’s technology are substantial for the cardiac care industry. Traditional ECG monitoring often requires bulky equipment or multiple leads that can be cumbersome for patients. HeartBeam’s cable-free, 3D approach could enable more convenient and continuous monitoring, potentially leading to earlier detection of arrhythmias and other cardiac conditions. This could reduce the burden on healthcare facilities by allowing more patients to be monitored at home, and may improve outcomes through timely intervention.
For investors, the upcoming conference call provides an opportunity to gauge the company’s progress in commercializing its platform and its strategy for global market penetration. The company’s focus on accelerating adoption suggests that HeartBeam is moving beyond regulatory milestones toward building a revenue-generating business. The call may also shed light on partnerships, reimbursement strategies, and clinical study plans.
The conference call details and additional information about HeartBeam’s technology and cleared indications for use are available on the company’s website at https://www.heartbeam.com/indications. Investors and interested parties can access the latest news and updates on the company at https://ibn.fm/BEAT.
